Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
GoodRx Holdings (GDRX) is back in focus after its Q2 2026 earnings report on 5 August, along with raised full-year revenue guidance and a leadership change that appoints Justin Fengler as Chief Financial Officer.
See our latest analysis for GoodRx Holdings.
The Q2 earnings update and CFO transition come after a period of sharp share price moves for GoodRx Holdings. The stock has a 90 day share price return of 44.18% and a year to date share price return of 30.55%. However, the 3 year total shareholder return has declined 50.41% and the 5 year total shareholder return has declined 89.72%, which suggests recent momentum contrasts with a much weaker long term record.
If GoodRx has you looking more closely at healthcare and technology, it can be useful to compare it with other companies using our screener of 43 healthcare AI stocks
GoodRx Holdings now trades at $3.59 after a sharp rebound, while longer term shareholders still sit on steep declines. Does the current valuation leave enough upside potential to compensate for the risks?
Most Popular Narrative: 13% Overvalued
GoodRx Holdings closed at $3.59 compared with a most followed narrative fair value of $3.18, which frames the current valuation debate for this stock.
Substantial momentum in the company's pharma manufacturer solutions (32% YoY revenue growth, with management projecting 30%+ in 2025) reflects strong demand for direct-to-patient engagement, unlocking higher-margin revenue streams and providing meaningful upside to consolidated revenue and net margins.
Curious what sits behind that confidence in higher margin pharma solutions and subscriptions. The narrative ties together revenue growth, margin lift and a future earnings multiple. Want to see how those building blocks combine into a single fair value path.
Result: Fair Value of $3.18 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, GoodRx still faces meaningful execution risks, including disruption from pharmacy benefit manager or pharmacy changes and pressure from larger competitors that could unsettle the current analyst narrative.
Find out about the key risks to this GoodRx Holdings narrative.
Another View on GoodRx Holdings Using Cash Flows
The analyst narrative suggests GoodRx Holdings is 13% overvalued at $3.59 compared with a fair value of $3.18. Our DCF model points in the opposite direction. It estimates future cash flows support a value of $9.64 per share, which is well above the current price and flags a very different risk reward balance. Which framework do you trust more when the signals split this far apart?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out GoodRx Holdings for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With GoodRx Holdings presenting both optimism and concern in this article, it makes sense to review the numbers yourself and test the assumptions on both sides. To quickly size up the trade off between potential upside and the issues investors are watching, take a look at the 2 key rewards and 2 important warning signs .
Looking for more investment ideas beyond GoodRx Holdings?
Do not stop with GoodRx Holdings. Use the tools available now to quickly scan fresh opportunities and keep your watchlist stocked with ideas that fit your style.
-
Target potential upside with companies that combine quality fundamentals and attractive pricing by checking the 49 high quality undervalued stocks .
-
Prioritise resilience by focusing on businesses screened for stronger balance sheets and healthier finances through the solid balance sheet and fundamentals stocks screener (49 results) .
-
Hunt for underfollowed opportunities that may not be on most radars yet by reviewing the screener containing 20 high quality undiscovered gems .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GDRX .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
